Add BrightSurf on Google Email

ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations

The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.

SourceECOG-ACRIN Cancer Research Group·TypeExperimental study·DateMar 16, 2022

Treating deadly mammary cancer with a novel plant virus-based immunotherapy

A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 14, 2022

Researchers find natural mechanism to sensitize cancer to immunotherapy

A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.

SourceMichigan Medicine - University of Michigan·JournalCancer Cell·TypeExperimental study·DateMar 4, 2022

Changing the standard of care for stage III melanoma surgery

Researchers found that patients with stage III melanoma who received immunotherapy alone had better rates of distant metastasis-free survival compared to those who underwent completion lymph node dissection. The study suggests that de-escalation of unnecessary therapies, such as CLND, may improve patient outcomes and reduce complications.

SourceUniversity of Colorado Anschutz Medical Campus·JournalAnnals of Surgical Oncology·DateMar 4, 2022

New precision technology for immunotherapy

Researchers at Lund University have developed a new precision medicine technology, TS-MAP, to identify and target cancer cell surface proteins. The method provides a direct analysis of all accessible cell surface tumour antigens in tumour tissue from patients.

SourceLund University·JournalProceedings of the National Academy of Sciences·DateFeb 28, 2022

Immunotherapy drug bolsters head and neck cancer treatment

A University of Cincinnati clinical trial showed promising results for patients with intermediate risk head and neck cancer when an immunotherapy drug, pembrolizumab, was added to standard treatment regimens. The study found improved one-year disease-free survival rates compared to historical controls.

SourceUniversity of Cincinnati·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateFeb 28, 2022

Researchers discover two treatments that induce peanut allergy remission in children

Two new treatments have been found to induce peanut allergy remission in children, with about half achieving remission and experiencing significant improvements in quality of life. The combination treatment and oral immunotherapy alone were both highly effective, providing substantial benefits for children's health and well-being.

SourceMurdoch Childrens Research Institute·JournalThe Lancet Child & Adolescent Health·TypeRandomized controlled/clinical trial·DateFeb 4, 2022

“Inflaming” cold tumors

Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.

SourceTechnical University of Munich (TUM)·JournalNature Cancer·TypeExperimental study·DateFeb 3, 2022

Immunotherapy with house dust mite extract reduces symptoms of atopic dermatitis

Researchers found sublingual immunotherapy with house dust mite extract to be effective in reducing signs and symptoms of atopic dermatitis. The treatment, administered over 18 months, resulted in significant improvements in pruritus and lesions, with rare side effects.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Allergy and Clinical Immunology: In Practice·TypeRandomized controlled/clinical trial·DateFeb 3, 2022

UCLA Jonsson Comprehensive Cancer Center scientists identify germline signature that predicts side effects from anti-PD1/PDL1 checkpoint therapy

Researchers have identified a germline biomarker signature that can predict serious side effects in up to 3 in 10 patients undergoing anti-PD1/PDL1 therapy. The findings represent an important step toward personalizing checkpoint therapy, potentially improving patient outcomes and reducing harm.

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal for ImmunoTherapy of Cancer·TypeImaging analysis·DateFeb 3, 2022

THE LANCET: Initiating peanut oral immunotherapy in peanut-allergic children under age four may be more effective, first long term study suggests

A randomised controlled trial found that most young children treated with peanut immunotherapy achieved desensitisation after two and a half years of treatment, while one in five remained in remission. Younger children under one year old were more likely to achieve remission, suggesting early interventions may provide better outcomes.

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJan 20, 2022

Scientists demonstrate utility of Bilateral Tumor Model for evaluating anti-cancer T-cell responses

A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.

SourceTokyo University of Science·JournalFrontiers in Immunology·TypeExperimental study·DateJan 19, 2022

Personalizing treatment for severe limb injuries

A team of scientists at the University of Missouri used small wearable sensors to gather data on how people with a traumatic hand amputation use a prosthesis versus a transplanted hand. The study found that hand transplant recipients exhibit a more balanced pattern of limb use, while prosthesis users rely heavily on their prosthetic hand.

SourceUniversity of Missouri-Columbia·JournalNeurorehabilitation and Neural Repair·DateJan 10, 2022

Sorting cancers by 'immune archetypes' represents potential new approach to developing precision immunotherapies

Researchers at UCSF identify unique immune microenvironments in different types of cancer, paving the way for personalized immunotherapies. The study categorizes tumors into 12 groups based on their immune profile, suggesting that some cancers share similar characteristics despite being from different types.

High-fiber diet associated with improved progression-free survival and response to immunotherapy in melanoma patients

Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.

Target identified to improve immunotherapy against solid tumors: the transcription factor Blimp1

Scientists have identified the transcription factor Blimp1 as a new critical regulator of tumor-infiltrating regulatory T cells. Disrupting Blimp1 in these cells remodels the tumor microenvironment and augments the response to immunotherapy, promoting improved tumor control and anti-tumor immunity.

SourceUniversity of Alabama at Birmingham·JournalMolecular Cancer·TypeExperimental study·DateDec 21, 2021

New treatment combination without chemotherapy is effective in PH+ acute lymphoblastic leukemia

A new treatment combination of dasatinib, blinatumomab, and prednisone has shown promise in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The trial achieved a three-year DFS rate of 80 percent and an overall survival rate of 85 percent for enrolled patients.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateDec 13, 2021

New review highlights cancer-crushing viruses

A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.

SourceArizona State University·JournalCancers·TypeLiterature review·DateNov 30, 2021

Personalized T cell immunotherapy for pediatric brain tumors is one step closer to becoming a reality

Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.

SourceChildren's National Hospital·JournalNature Communications·DateNov 18, 2021

UCLA scientists make strides toward an ‘off-the-shelf’ immune cell therapy for cancer

Researchers produce large quantities of powerful cancer-fighting iNKT cells using stem cell engineering and organoid technology, offering a potential solution for mass-producing an off-the-shelf immune cell therapy. The therapy, which uses hematopoietic stem cell-engineered iNKT cells, has been shown to be effective in killing multiple...

SourceUniversity of California - Los Angeles Health Sciences·JournalCell Reports Medicine·TypeExperimental study·DateNov 16, 2021

Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases

A Phase II study shows that combination treatment with nivolumab and ipilimumab improves overall survival in patients with asymptomatic melanoma brain metastases, with an overall survival rate of 71.9% at three years. The treatment demonstrates durable responses, even in symptomatic patients.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateNov 10, 2021

Immunotherapy may yield longer treatment-free survival than targeted therapy in advanced renal cell carcinoma patients

Patients with advanced renal cell carcinoma treated with checkpoint inhibitor combination nivolumab plus ipilimumab experienced longer treatment-free survival compared to those receiving targeted therapy sunitinib. The analysis revealed significant differences in how patients spent their overall survival time between the two treatments.

SourceAmerican Association for Cancer Research·JournalClinical Cancer Research·DateNov 10, 2021

Model predicts early response to cancer immunotherapy

Researchers developed a mathematical model that can predict the effectiveness of immunotherapy treatment for individual patients based on standard clinical measures. The model showed high sensitivity in predicting treatment response within two months, with minimal false-negative results.

SourceeLife·JournaleLife·DateNov 9, 2021

Penn study finds solid-tumor cancer patients ineligible for clinical trials receive immunotherapy at greater rates despite lack of benefits

A nationwide study published in JAMA Oncology found that immunotherapy use among trial-ineligible solid-tumor cancer patients increased significantly between 2014 and 2019, yet no survival benefit was observed. Researchers emphasize cautious use of immunotherapies for this population due to potential early harm.

SourceUniversity of Pennsylvania School of Medicine·JournalJAMA Oncology·TypeMeta-analysis·DateNov 9, 2021

Nature Medicine publishes phase 2 trial data showing durvalumab immunotherapy with standard chemotherapy improved survival in malignant pleural mesothelioma

A phase 2 clinical trial shows durvalumab immunotherapy combined with standard chemotherapy significantly improved overall survival for patients with previously untreated malignant pleural mesothlioma. The study's findings provide insights into patient selection methods for this novel chemo-immunotherapy regimen.

SourcePrECOG, LLC·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateNov 8, 2021

Hollings collaborates on two studies showing how to boost immunotherapy effectiveness for patients with oral-cavity squamous cell carcinoma

Researchers from MUSC Hollings Cancer Center, UCLA Jonsson Comprehensive Cancer Center, and Winship Cancer Institute discovered that pre-surgical anti-PD-1 immunotherapy is safe and effective for OCSCC patients. The studies identified potential molecular biomarkers in blood and tumors to predict treatment response.

SourceMedical University of South Carolina·JournalCell Reports Medicine·DateOct 29, 2021